Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy

Lung cancer remains the leading cause of cancer death worldwide despite the significant progress made by immune checkpoint inhibitors, including programmed death receptor-1 (PD1)/PD ligand 1 (PDL1)-blockade therapy. PD1/PDL1−blockade has achieved unprecedented tumor regression in some patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Poznanski, Sophie M, Ritchie, Tyrah M, Fan, Isabella Y, El-Sayes, Abdullah, Portillo, Ana L, Ben-Avi, Ronny, Rojas, Eduardo A, Chew, Marianne V, Shargall, Yaron, Ashkar, Ali A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825270/
https://www.ncbi.nlm.nih.gov/pubmed/33479024
http://dx.doi.org/10.1136/jitc-2020-001933

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825270/
https://www.ncbi.nlm.nih.gov/pubmed/33479024
http://dx.doi.org/10.1136/jitc-2020-001933

Ejemplares similares